Targeting apoptosis by hydroxymethylacylfulvene in combination with gamma radiation in prostate tumor cells
B A Woynarowska1, K Roberts, J M Woynarowski
1Department of Radiation Oncology, University of Texas Health Science Center, San Antonio, Texas 78284, USA.
Abstract:
Hydroxymethylacylfulvene (HMAF) is a novel agent with alkylating activity and is a potent inducer of apoptosis that is currently undergoing Phase II clinical trials for prostate cancer. This study explored the pro-apoptosis and anti-proliferative potential of HMAF in combination with gamma radiation in human prostate tumor cell lines. Apoptosis was assessed based on the generation of fragmented DNA, a terminal transferase flow cytometry assay, and cell morphology. In each of the tumor cell lines examined, radiation alone induced a marginal level of apoptosis, even after a prolonged 48-h incubation after exposure. In contrast, HMAF alone was a potent inducer of apoptosis in prostate tumor cells but not in normal cells. Marked levels of apoptosis in tumor cells were also observed for the combination of HMAF with gamma radiation. When drug treatment preceded irradiation, at least additive levels of apoptosis were observed in both androgen-responsive and androgen-independent cells. The combined treatment with ionizing radiation and HMAF reduced the radiation dose needed for the same level of clonogenic survival up to 2.5-fold. The potentiation of apoptosis and reduction in the clonogenic survival of tumor cells occurred at HMAF concentrations lower than that which reduced survival to 10% and at doses up to 6 Gy. No potentiation of apoptosis or clonogenic inhibition was noted in normal cells. These results suggest that the combination of HMAF with gamma radiation may have clinical utility for treatments of prostate cancer.
Insights
Hydroxymethylacylfulvene (HMAF) combined with gamma radiation effectively induces apoptosis and inhibits proliferation in prostate cancer cells. This combination therapy shows promise for treating prostate cancer, sparing normal cells.
Area of Science:
- Oncology
- Cancer Research
- Radiotherapy
Background:
- Hydroxymethylacylfulvene (HMAF) is an investigational agent with alkylating properties and potent apoptosis-inducing capabilities.
- HMAF is currently in Phase II clinical trials for prostate cancer treatment.
- Understanding combination therapies is crucial for enhancing treatment efficacy in prostate cancer.
Purpose of the Study:
- To investigate the synergistic pro-apoptosis and anti-proliferative effects of HMAF in combination with gamma radiation.
- To evaluate the efficacy of this combination therapy on human prostate tumor cell lines.
- To assess the safety profile of the combination therapy on normal cells.
Main Methods:
- Human prostate tumor cell lines were treated with HMAF alone, gamma radiation alone, or a combination of both.
- Apoptosis was quantified using DNA fragmentation assays, terminal transferase flow cytometry, and cell morphology analysis.
- Clonogenic survival assays were performed to assess the impact on cell proliferation.
Main Results:
- HMAF alone potently induced apoptosis in prostate tumor cells, with minimal effect on normal cells.
- The combination of HMAF and gamma radiation resulted in significantly increased apoptosis in tumor cells compared to either agent alone.
- Combined treatment reduced the required radiation dose for clonogenic survival by up to 2.5-fold, with no observed potentiation of apoptosis or inhibition in normal cells.
Conclusions:
- The combination of HMAF and gamma radiation demonstrates significant pro-apoptotic and anti-proliferative activity against prostate cancer cells.
- This combination therapy exhibits a favorable therapeutic window, targeting tumor cells while sparing normal tissues.
- These findings suggest a potential clinical utility for HMAF and gamma radiation combination therapy in prostate cancer treatment.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...